ASH 2020 | MaaT013: a next-gen fecal microbiota transfer product shows promise in GvHD

Name: MaaT013: a next-gen fecal microbiota transfer product shows promise in GvHD
Uploaded: 2020-12-07T00:00:00Z
Duration: 4 min 20 s

Mohamad Mohty • 7 Dec 2020

ASH 2020

General MaaT013 Ruxolitinib

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the results of a study aiming to improve prognosis in patients with intestinal graft-versus-host disease (GvHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Treatment of intestinal GvHD is an unmet need, with no therapeutic options beyond steroid therapy. A next-generation fecal microbiota transfer (FMT) product, MaaT013, was administered to 29 patients with steroid-dependent or steroid refractory GvHD as part of a compassionate use/expanded access program. The microbiota biotherapeutic led to impressive response rates, with some patients achieving complete remission. MaaT013 was also found to have a promising safety profile. These findings suggest that the use of microbiota could become a key approach in treating severe GvHD. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.